Brokerages predict that ContraFect Corp (NASDAQ:CFRX) will post ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ContraFect’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.09). ContraFect posted earnings of ($0.15) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that ContraFect will report full-year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.32). For the next fiscal year, analysts forecast that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow ContraFect.
Institutional investors have recently modified their holdings of the company. Birchview Capital LP boosted its position in shares of ContraFect by 56.5% during the 3rd quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after acquiring an additional 410,000 shares in the last quarter. 683 Capital Management LLC acquired a new stake in shares of ContraFect during the 3rd quarter valued at about $2,886,000. Finally, Fosun International Ltd acquired a new stake in shares of ContraFect during the 3rd quarter valued at about $9,435,000. Institutional investors and hedge funds own 62.47% of the company’s stock.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.